Abstract
Several effective drugs have become available for prostate cancer therapy, which are being used after the development of castration resistance and studied already at an earlier stage of prostate cancer therapy. Novel hormonally acting drugs include degarelix, enzalutamide and abiraterone. Cytotoxic agents that have proven effective in studies include the docetaxel derivative cabazitaxel, denosumab in the prevention of complications caused by bone metastases, and radium-233 chloride as treatment for bone metastases. The optimal sequence of administration of the novel drugs as well as combining them are subject to intensive research.
| Original language | Finnish |
|---|---|
| Pages (from-to) | 923-930 |
| Number of pages | 8 |
| Journal | Duodecim |
| Volume | 129 |
| Issue number | 9 |
| Publication status | Published - 2013 |
| Publication type | A2 Review article in a scientific journal |
Publication forum classification
- Publication forum level 1
